Search

Displaying results 3031 - 3040 of 8575 in total
  1. Drug

    Zofin

    go.drugbank.com/drugs/DB16519
    Investigational

    Zofin, previously known as Organicell Flow, is a nanoparticle-based therapeutic derived from perinatal sources which is manufactured in a way that retains the naturally occurring microRNAs without the

  2. Drug

    Edoxaban

    go.drugbank.com/drugs/DB09075
    ApprovedInvestigational

    This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. … Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for

  3. Drug

    BMS-582949

    go.drugbank.com/drugs/DB12696
    Investigational

    BMS-582949 has been investigated for the treatment of Psoriasis.

  4. Drug

    GTI 2040

    go.drugbank.com/drugs/DB05801
    Investigational

    GTI-2040 is a substance that is being studied as a treatment for cancer. It belongs to the family of drugs called antisense oligonucleotides.

  5. Drug

    Bleomycin A6

    go.drugbank.com/drugs/DB12992
    Investigational

    Bleomycin A6 (also known as boanmycin) has been used in trials studying the treatment of Squamous Cell Lung Cancer. It was developed in China as an antineoplastic antibiotic. … The development of this drug, apparently, was discontinued.

  6. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older. … [L26656] Developed by BioCryst Pharmaceuticals, berotralstat is marketed under the name Orladeyo as oral capsules.

  7. Drug

    LM-609

    go.drugbank.com/drugs/DB05787
    Experimental

    LM-609 (Vitaxin) is an artificial antibody that targets a protein on the surface of newly forming blood vessels, as well as on certain tumors. … In addition to cancer, the protein has been implicated in bone destruction in rheumatoid arthritis and the inflammatory process in psoriasis.

  8. Drug

    AN-9

    go.drugbank.com/drugs/DB05103
    Investigational

    than BA in preclinical studies. … It shows greater potency than BA at inducing malignant cell differentiation and tumor growth inhibition and has demonstrated more favorable toxicological, pharmacological, and pharmaceutical properties

  9. Drug

    Efonidipine

    go.drugbank.com/drugs/DB09235
    Investigational

    Initially, it was marketed in 1995 under the trade name, _Landel_. The drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. … It has also been studied in atherosclerosis and acute renal failure [A32001]. This drug is also known as NZ-105, and several studies have been done on its pharmacokinetics in animals [L1456].

  10. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    It was approved by the FDA on March 26, 2019 [L5792] and by Health Canada on February 20, 2020. … Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS).